兰州大学学报(医学版)

参考文献

[1] LEDFORD H. The mysteries of inflammatory bowel disease are being cracked-offering hope for new therapies[J].Nature,2024,632(8027):963-964.

[2] ILIEV I D,ANANTHAKRISHNAN A N,GUO C J. Microbiota in inflammatory bowel disease:mechanisms of disease and therapeutic opportunities[J/OL].(2025-03-10)[2025-04-10]. Nature reviews Microbiology,2025:1-16. https://pubmed.ncbi.nlm.nih.gov/40065181/.

[3] ZHANG F,ASCHENBRENNER D,YOO J Y,et al. The gut mycobiome in health,disease,and clinical applications in association with the gut bacterial microbiome assembly[J]. The lancet microbe,2022,3(12):e969-e983.

[4] SANTANA P T,ROSAS S L B,RIBEIRO B E,et al.Dysbiosis in inflammatory bowel disease:pathogenic role and potential therapeutic targets[J]. International journal of molecular sciences,2022,23(7):3464.

[5] JU L,SUO Z M,LIN J,et al. Fecal microbiota and metabolites in the pathogenesis and precision medicine for inflammatory bowel disease[J]. Precision clinical medicine,2024,7(3):pbae023.

[6] KUMBHARI A,CHENG T N H,ANANTHAKRISHN AN A N,et al. Discovery of disease-adapted bacterial lineages in inflammatory bowel diseases[J]. Cell host&microbe,2024,32(7):1147-1162.e12.

[7] NING L J,ZHOU Y L,SUN H,et al. Microbiome and metabolome features in inflammatory bowel disease via multiomics integration analyses across cohorts[J]. Nature communications,2023,14(1):7135.

[8] YAN Q L,LI S H,YAN Q S,et al. A genomic compendium of cultivated human gut fungi characterizes the gut mycobiome and its relevance to common diseases[J].Cell,2024,187(12):2969-2989.e24.

[9] SOKOL H,LEDUCQ V,ASCHARD H,et al. Fungal microbiota dysbiosis in IBD[J]. Gut,2017,66(6):1039-1048.

[10] RAHABI M,JACQUEMIN G,PRAT M,et al. Divergent roles for macrophage C-type lectin receptors,dectin-1 and mannose receptors,in the intestinal inflammatory response[J]. Cell reports,2020,30(13):4386-4398.e5.

[11] LIMON J J,TANG J,LI D L,et al. Malassezia is associated with Crohn’s disease and exacerbates colitis in mouse models[J]. Cell Host&microbe,2019,25(3):377-388.e6.

[12] MARONEK M,LINK R,AMBRO L,et al. Phages and their role in gastrointestinal disease:focus on inflammatory bowel disease[J]. Cells,2020,9(4):1013.

[13] ZUO T,LU X J,ZHANG Y,et al. Gut mucosal virome alterations in ulcerative colitis[J]. Gut,2019,68(7):1169-1179.

[14] TITO R Y,CHAFFRON S,CAENEPEEL C,et al.Population-level analysis of Blastocystis subtype prevalence and variation in the human gut microbiota[J].Gut,2019,68(7):1180-1189.

[15] HAN G,VAISHNAVA S. Microbial underdogs:exploring the significance of low-abundance commensals in host-microbe interactions[J]. Experimental&molecular medicine,2023,55(12):2498-2507.

[16] CARUSO R,LO B C,CHEN G Y,et al. Host-pathobiont interactions in Crohn’s disease[J]. Nature reviews gastroenterology&hepatology,2025,22(6):395-414.

[17] SPINDLER M P,SIU S,MOGNO I,et al. Human gut microbiota stimulate defined innate immune responses that vary from phylum to strain[J]. Cell host&microbe,2022,30(10):1481-1498.e5.

[18] SMITH P M,HOWITT M R,PANIKOV N,et al. The microbial metabolites,short-chain fatty acids,regulate colonic Treg cell homeostasis[J]. Science,2013,341(6145):569-573.

[19] QIU X Y,ZHANG M M,YANG X T,et al. Faecalibacterium prausnitzii upregulates regulatory T cells and antiinflammatory cytokines in treating TNBS-induced colitis[J]. Journal of Crohn’s and colitis,2013,7(11):e558-e568.

[20] ZHAO W Q,LI S X,LI Q Q,et al. Mendelian randomization reveals predictive,preventive,and personalized insights into inflammatory bowel disease:the role of gut microbiome and circulating inflammatory proteins[J].The EPMA journal,2024,15(4):693-709.

[21] ERDMAN S E,RAO V P,POUTAHIDIS T,et al. Nitric oxide and TNF-alpha trigger colonic inflammation and carcinogenesis in Helicobacter hepaticus-infected,Rag2-deficient mice[J]. Proceedings of the national academy of sciences of the United States of America,2009,106(4):1027-1032.

[22] GILLILAND A,CHAN J J,DE WOLFE T J,et al.Pathobionts in inflammatory bowel disease:origins ,underlying mechanisms,and implications for clinical care[J]. Gastroenterology,2024,166(1):44-58.

[23] ROLHION N,DARFEUILLE-MICHAUD A. Adherentinvasive Escherichia coli in inflammatory bowel disease[J]. Inflammatory bowel diseases,2007,13(10):1277-1283.

[24] NI J,WU G D,ALBENBERG L,et al. Gut microbiota and IBD:causation or correlation[J]. Nature reviews gastroenterology&hepatology,2017,14(10):573-584.

[25] LIU Z J,LIU R Z,GAO H,et al. Genetic architecture of the inflammatory bowel diseases across East Asian and European ancestries[J]. Nature genetics,2023,55(5):796-806.

[26] RAMANAN D,TANG M S,BOWCUTT R,et al. Bacterial sensor Nod2 prevents inflammation of the small intestine by restricting the expansion of the commensal Bacteroides vulgatus[J]. Immunity,2014,41(2):311-324.

[27] LARABI A,BARNICH N,NGUYEN H T T. New insights into the interplay between autophagy,gut microbiota and inflammatory responses in IBD[J]. Autophagy,2020,16(1):38-51.

[28] COHEN L J,CHO J H,GEVERS D,et al. Genetic factors and the intestinal microbiome guide development of microbe-based therapies for inflammatory bowel diseases[J]. Gastroenterology,2019,156(8):2174-2189.

[29] LAVOIE S,CONWAY K L,LASSEN K G,et al. The Crohn’s disease polymorphism,ATG16L1 T300A,alters the gut microbiota and enhances the local Th1/Th17response[J]. eLife,2019,8:e39982.

[30] LAMAS B,RICHARD M L,LEDUCQ V,et al. CARD9impacts colitis by altering gut microbiota metabolism of tryptophan into aryl hydrocarbon receptor ligands[J].Nature medicine,2016,22(6):598-605.

[31] PNG C W,LINDéN S K,GILSHENAN K S,et al.Mucolytic bacteria with increased prevalence in IBD mucosa augment in vitro utilization of mucin by other bacteria[J]. The American journal of gastroenterology,2010,105(11):2420-2428.

[32] KUDELKA M R,STOWELL S R,CUMMINGS R D,et al. Intestinal epithelial glycosylation in homeostasis and gut microbiota interactions in IBD[J]. Nature reviews gastroenterology&hepatology,2020,17(10):597-617.

[33] LIU S,ZHAO W J,LAN P,et al. The microbiome in inflammatory bowel diseases:from pathogenesis to therapy[J]. Protein&cell,2021,12(5):331-345.

[34] KEDIA S,RAMPAL R,PAUL J,et al. Gut microbiome diversity in acute infective and chronic inflammatory gastrointestinal diseases in North India[J]. Journal of gastroenterology,2016,51(7):660-671.

[35] LLOYD-PRICE J,ARZE C,ANANTHAKRISHNAN A N ,et al. Multi-omics of the gut microbial ecosystem in inflammatory bowel diseases[J]. Nature,2019,569(7758):655-662.

[36] SANMARCO L M,CHAO C C,WANG Y C,et al.Identification of environmental factors that promote intestinal inflammation[J]. Nature,2022,611(7937):801-809.

[37] GAO H,SUN M M,LI A,et al. Microbiota-derived IPA alleviates intestinal mucosal inflammation through upregulating Th1/Th17 cell apoptosis in inflammatory bowel disease[J]. Gut microbes,2025,17(1):2467235.

[38] HERTZ S,ANDERSON J M,NIELSEN H L,et al. Fecal microbiota is associated with extraintestinal manifestations in inflammatory bowel disease[J]. Annals of medicine,2024,56(1):2338244.

[39] CLOONEY A G,ECKENBERGER J,LASERNA-MEN DIETA E,et al. Ranking microbiome variance in inflammatory bowel disease:a large longitudinal intercontinental study[J]. Gut,2021,70(3):499-510.

[40] SERRANO-GóMEZ G,MAYORGA L,OYARZUN I,et al. Dysbiosis and relapse-related microbiome in inflammatory bowel disease:a shotgun metagenomic approach[J]. Computational and structural biotechnology journal,2021,19:6481-6489.

[41] GAO S,GAO X,ZHU R X,et al. Microbial genes outperform species and SNVs as diagnostic markers for Crohn’s disease on multicohort fecal metagenomes empowered by artificial intelligence[J]. Gut microbes,2023,15(1):2221428.

[42] ANANTHAKRISHNAN A N,WHELAN K,ALLEGR ETTI J R,et al. Diet and microbiome-directed therapy2.0 for IBD[J]. Clinical gastroenterology and hepatology,2025,23(3):406-418.

[43] VALCHEVA R,KOLEVA P,MARTíNEZ I,et al. Inulin-type fructans improve active ulcerative colitis associated with microbiota changes and increased short-chain fatty acids levels[J]. Gut microbes,2019,10(3):334-357.

[44] FACCHIN S,VITULO N,CALGARO M,et al. Microbiota changes induced by microencapsulated sodium butyrate in patients with inflammatory bowel disease[J].Neurogastroenterology&motility,2020,32(10):e13914.

[45] WONG W Y,CHAN B D,LEUNG T W,et al. Beneficial and anti-inflammatory effects of formulated prebiotics,probiotics,and synbiotics in normal and acute colitis mice[J]. Journal of functional foods,2022,88:104871.

[46] BAUNWALL S M D,ANDREASEN S E,HANSEN M M,et al. Faecal microbiota transplantation for first or second Clostridioides difficile infection(EarlyFMT):a randomised,double-blind,placebo-controlled trial[J].The lancet gastroenterology&hepatology,2022,7(12):1083-1091.

[47] ALLEGRETTI J R,KELLY C R,GRINSPAN A,et al.Outcomes of fecal microbiota transplantation in patients with inflammatory bowel diseases and recurrent Clostridioides difficile infection[J]. Gastroenterology,2020,159(5):1982-1984.(下转第23页)

[48] IMDAD A,PANDIT N G,ZAMAN M,et al. Fecal transplantation for treatment of inflammatory bowel disease[J]. Cochrane database of systematic reviews,2023,4(4):CD012774.

[49] PARAMSOTHY S,KAMM M A,KAAKOUSH N O,et al. Multidonor intensive faecal microbiota transplantation for active ulcerative colitis:a randomised placebocontrolled trial[J]. The lancet,2017,389(10075):1218-1228.

[50] ESKENAZI A,LOOD C,WUBBOLTS J,et al. Combination of pre-adapted bacteriophage therapy and antibiotics for treatment of fracture-related infection due to pandrug-resistant Klebsiella pneumoniae[J]. Nature communications,2022,13(1):302.

[51] FEDERICI S,KREDO-RUSSO S,VALDéS-MAS R,et al. Targeted suppression of human IBD-associated gut microbiota commensals by phage consortia for treatment of intestinal inflammation[J]. Cell,2022,185(16):2879-2898.e24.

[52] LEE Y,SUGIHARA K,GILLILLAND M G 3RD,et al.Hyaluronic acid-bilirubin nanomedicine for targeted modulation of dysregulated intestinal barrier,microbiome and immune responses in colitis[J]. Nature materials,2020,19(1):118-126.

[53] ZHAO Y D,ZHU M N,LING Y F,et al. A DNA nanopatch-bacteriophage system targeting Streptococcus gallolyticus for inflammatory bowel disease treatment and colorectal cancer prevention[J]. Advanced materials,2025,37(11):e2417334.

[54] KAN L L,ZHENG Z W,FU W Y,et al. Recent progress on engineered micro/nanomaterials mediated modulation of gut microbiota for treating inflammatory bowel disease[J]. Journal of controlled release ,2024 ,370:43-65.